Valuation
$3.7B
Funding
$792M
Team
51
Founded
2012
Abogen revenue, CEO Bo Ying, team size, customer count, churn, and more in 2026.
Abogen Biosciences is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics for the treatment of cancer and infectious diseases. The company was founded in 2019 and is based in Suzhou, China, with a focus on advanced technologies for drug delivery.
Last updated
Abogen Revenue
We do not have information about Abogen's revenue yet.
Abogen Valuation, Funding Rounds
Abogen reached a $3.7B valuation in 2021, set during its Series B round.
Abogen has raised $792M in total funding across 2 rounds, most recently a $700M Series C round in 2021.
| Year | Round | Amount | Valuation | % Sold |
|---|---|---|---|---|
| 2021 | Series C | $700M | - | - |
| 2021 | Series B | $92M | $3.7B | 2% |
Abogen Employees & Team Size
Abogen employs approximately 51 people as of 2026.
Abogen has 51 total employees in different roles and functions.
| Year | Milestone |
|---|---|
| 2025 | Reached 51 employees (November 2025) |
Founder / CEO
Q&A
| Question | Answer |
|---|---|
| What's your age? | - |
| Favorite online tool? | - |
| Favorite book? | - |
| Favorite CEO? | - |
| Advice for 20 year old self | - |
Customers
We do not have customer count information for Abogen yet.
Frequently Asked Questions about Abogen
What is Abogen's revenue?
GetLatka has not confirmed a public revenue figure for Abogen.
Who founded Abogen?
Abogen was founded by Bo Ying.
Who is the CEO of Abogen?
The CEO of Abogen is Bo Ying.
How much funding does Abogen have?
Abogen raised $792M.
How many employees does Abogen have?
Abogen has 51 employees.
Where is Abogen headquarters?
Abogen is headquartered in Suzhou, China.
Source Attribution
Source: all data was collected from GetLatka company research and founder interviews. Revenue, funding, team, and customer figures are presented as company-reported or GetLatka-estimated metrics where the profile data identifies them that way.
Company data last updated .